Co-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy

BACKGROUND: Chimeric antigen receptor (CAR)-T cell therapy is a powerful adoptive immunotherapy against both B-cell malignancies and some types of solid tumors. Interleukin (IL) -15 is an important immune stimulator that may provide ideal long-term persistent CAR-T cells. However, higher base line o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ying, Zhuang, Qinghui, Wang, Fang, Zhang, Can, Xu, Chang, Gu, Aiqin, Zhong, William H., Hu, Yi, Zhong, Xiaosong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516829/
https://www.ncbi.nlm.nih.gov/pubmed/36167591
http://dx.doi.org/10.1186/s12967-022-03626-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516829/
https://www.ncbi.nlm.nih.gov/pubmed/36167591
http://dx.doi.org/10.1186/s12967-022-03626-x

Ejemplares similares